Patents
Literature
25 results about "Interleukin 13" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Interleukin 13 (IL-13) is a protein that in humans is encoded by the IL13 gene. IL-13 was first cloned in 1993 and is located on chromosome 5q31 with a length of 1.4kb. It has a mass of 13 kDa and folds into 4 alpha helical bundles. The secondary structural features of IL-13 are similar to that of Interleukin 4 (IL-4); however it only has 25% sequence homology to IL-4 and is capable of IL-4 independent signaling. IL-13 is a cytokine secreted by T helper type 2 (Th2) cells, CD4 cells, Natural killer T cell, Mast cell, Basophil cells, Eosinophil cells and Nuocyte cells. Interleukin-13 is a central regulator in IgE synthesis, goblet cell hyperplasia, mucus hypersecretion, airway hyperresponsiveness, fibrosis and chitinase up-regulation. It is a mediator of allergic inflammation and different diseases including asthma.
Antibodies that bind interleukin 13 and methods of use
Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13 and / or IgE.
Owner:APOGEE THERAPEUTICS INC
Anti-il-13 antibody and use thereof
PCT designated stageWO2026086810A1Hybrid immunoglobulinsImmunoglobulins against cytokines/lymphokines/interferonsDiseaseAntiendomysial antibodies
The present disclosure relates to an anti-interleukin 13 (IL-13) antibody and the use thereof, and specifically relates to an antibody or antigen-binding fragment thereof that specifically binds to human IL-13, a multispecific antigen-binding molecule, an isolated nucleic acid molecule, a vector, a cell, a pharmaceutical composition, the pharmaceutical use, a method for treating a disease, etc. The anti-IL-13 antibody of the present disclosure can significantly inhibit IL-13-induced proliferation of TF-1 cells, can specifically bind to human IL-13 proteins and has relatively high affinity.
Owner:HAINAN SIMCERE PHARMA CO LTD
Fusion protein comprising il13
The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration.
Owner:SYNERKINE PHARMA BV
A fusion protein comprising IL13
The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. 5 The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration. 20 26 21 41 00 10 A ug 2 02 6 1 0 A u g 2 0 2 6 2 0 2 6 2 1 4 1 0 0
Owner:SYNERKINE PHARMA BV
Il-13 antigen binding proteins
PCT designated stageWO2026114819A1Immunoglobulins against cytokines/lymphokines/interferonsImmunological disordersWhite blood cellAntigen binding
The present disclosure relates to antigen binding proteins that bind to one or more cytokines. In particular, the present disclosure provides interleukin 13 (IL-13) binding proteins as well as multispecific antigen binding proteins comprising an IL-13 binding domain. The present disclosure further relates to the use of said binding proteins in medicine.
Owner:GLAXOSMITHKLINE INTPROP DEV LTD
Antibodies that bind interleukin 13 and TSLP or tslpr and methods of use
PCT designated stage expiredWO2024264003A2Immunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsDiseaseAntiendomysial antibodies
Described herein are novel bispecific antibodies that bind Interleukin 13 (IL-13) and TSLP or TSLPR and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 and TSLP or TSLPR biological activities. In certain aspects, described herein are pharmaceutical compositions comprising the bispecific antibodies that bind Interleukin 13 (IL-13) and TSLP or TSLPR. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13, and / or IgE, and TSLP or TSLPR
Owner:PARAGON THERAPEUTICS INC
Use and methods of IL-2, IL-13 and IL-4 cytokine bifunctional molecules
PendingCN119156405AAntibody mimetics/scaffoldsPeptide/protein ingredientsPharmaceutical drugInterleukin II
Human interleukin 2 (IL-2), human interleukin 13 (IL-13), and / or human interleukin 4 (IL-4) cytokine fusions are provided. In particular, IL-2, IL-4, and / or IL-13 cytokine fusions are provided for use in monotherapeutic applications as well as in combination therapies to treat cancer. Also provided are pharmaceutical compositions comprising such IL-2, IL-4, and / or IL-13 cytokine fusions.
Owner:MEDICENNA THERAPEUTICS INC
Antibodies binding interleukin 13 and TSLP or tslpr and methods of use thereof
PendingCN121816362AImmunoglobulins against cytokines/lymphokines/interferonsImmunoglobulins against growth factorsDiseaseAntiendomysial antibodies
Described herein are novel bispecific antibodies that bind to interleukin 13 (IL-13) and TSLP or TSLPR and methods of use thereof. In certain aspects, described herein are methods of inhibiting the biological activity of IL-13 and TSLP or TSLPR. In certain aspects, described herein are pharmaceutical compositions comprising a bispecific antibody that binds to interleukin 13 (IL-13) and TSLP or TSLPR. In certain aspects, the antibodies and methods described herein are useful for the treatment of inflammatory diseases or disorders associated with elevated levels of IL-13 and / or IgE as well as TSLP or TSLPR.
Owner:PARAGON THERAPEUTICS INC
Fusion protein comprising IL13
The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration.
Owner:SYNERKINE PHARMA BV
Antibodies that bind interleukin 13 and methods of use
Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13 and / or IgE.
Owner:APOGEE THERAPEUTICS INC
Therapeutic variable domain of heavy chain (VHH) antibodies neutralizing interleukin 13 (il-13)
The present invention provides VHH antibodies that neutralize the pro-inflammatory cytokine interleukin IL-13 and their uses for treatment of inflammatory, fibrotic and other diseases and disorders.
Owner:MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV
Methods of administering antibodies that bind interleukin 13
PCT designated stageWO2026080829A1Immunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntiendomysial antibodiesAtopic dermatitis
Described herein are methods of administration of antibodies that bind interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disorder or disease, such as atopic dermatitis.
Owner:APOGEE THERAPEUTICS INC
Microorganism and composition comprising same
A novel Lactobacillus rhamnosus KBL2290 strain exhibits various activities such as improving intestinal flora, anti-inflammatory, and strengthening intestinal tight junctions. The strain may increase intestinal flora of Akkermansia genus, Lactobacillus genus, Ruminococcus genus or Prevotella genus, suppress an expression of interleukin 1-beta (IL-1B), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 12p40 (IL-12p40), interleukin 13 (IL-13), or interleukin 17A (IL-17A), suppresses an expression of chemokine ligand 2 (CCL2) or chemokine ligand 1 (CXCL1), suppress an expression of cyclooxygenase 2 (Cox-2) or nitric oxide synthase (iNOS), promote an expression of interleukin 10 (IL-10) or transforming growth factor-β (TGF-β), and increase an expression of Zo-1 or Occludin. A pharmaceutical composition including the strain may prevent or treat inflammatory bowel disease.
Owner:SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Kit for chemiluminiscence detection of interleukin 13 and application of kit
PendingCN120847076AChemiluminescene/bioluminescencePreparing sample for investigationAntiendomysial antibodiesMagnetic bead
The invention discloses a kit for chemiluminiscence detection of interleukin 13 and application of the kit. The kit comprises a reagent R1, a reagent R2 and a reagent R3, the reagent R1 comprises a magnetic bead, and the surface of the magnetic bead is coated with streptavidin; the reagent R2 and the reagent R3 respectively comprise an interleukin 13 monoclonal antibody 1 and an interleukin 13 monoclonal antibody 2, and the interleukin 13 monoclonal antibody 1 and the interleukin 13 monoclonal antibody 2 are respectively coupled with biotin and alkaline phosphatase. The kit has the advantages of being high in sensitivity, wide in linear range, simple in sample treatment and high in automation degree when being applied to detection of the interleukin 13, and has the application prospect of being applied to clinical determination of the concentration of the interleukin 13 in a serum or plasma sample.
Owner:ANHUI TONGKE BIOTECHNOLOGY CO LTD
Antibodies that bind interleukin 13 and methods of use
Described herein are novel and improved antibodies that bind to interleukin 13 (IL-13) and methods of use thereof. In certain aspects, methods of inhibiting the biological activity of IL-13 are described herein. In certain aspects, pharmaceutical compositions comprising the anti-IL-13 antibodies are described herein. In certain aspects, the antibodies and methods described herein are used to treat inflammatory diseases or disorders associated with elevated levels of IL-13 and / or IgE.
Owner:TINGFENG THERAPY CO LTD
Methods of administering antibodies that bind interleukin 13
PCT designated stage expiredWO2024227141A9Immunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntiendomysial antibodiesInterleukin 13
Described herein are methods of administration of antibodies that bind interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL‑13 biological activity. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disorder or disease.
Owner:APOGEE THERAPEUTICS INC
Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof
PCT designated stageWO2026085419A3Immunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntiendomysial antibodiesWhite blood cell
Described herein are compositions and combinations comprising an antibody that binds Interleukin 13 (IL-13) and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient.
Owner:APOGEE THERAPEUTICS INC
Antibodies that bind interleukin 13 and TSLP or tslpr and methods of use
Described herein are novel bispecific antibodies that bind Interleukin 13 (IL-13) and TSLP or TSLPR and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 and TSLP or TSLPR biological activities. In certain aspects, described herein are pharmaceutical compositions comprising the bispecific antibodies that bind Interleukin 13 (IL-13) and TSLP or TSLPR. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13, and / or IgE, and TSLP or TSLPR
Owner:PARAGON THERAPEUTICS INC
Pharmaceutical formulations of antibodies that bind interleukin 13
Pharmaceutical formulations of interleukin (IL)-13 antibodies are described herein. Pharmaceutical formulations for use in treating an inflammatory disorder or disease are also provided.
Owner:TINGFENG THERAPY CO LTD
Antibodies that bind il-13 in combination with hyaluronidase or a variant thereof
PCT designated stageWO2026085419A2Immunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntiendomysial antibodiesWhite blood cell
Described herein are compositions and combinations comprising an antibody that binds Interleukin 13 (IL-13) and a hyaluronidase or variant thereof, as well as related methods of treating an inflammatory disorder or disease in a human patient.
Owner:APOGEE THERAPEUTICS INC
Pharmaceutical formulations of antibodies that bind interleukin 13
PCT designated stage expiredWO2025137523A3Immunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntiendomysial antibodiesWhite blood cell
Described herein are pharmaceutical formulations of interleukin (IL)- 13 antibodies. Also provided are pharmaceutical formulations for use in the treatment of an inflammatory disorder or disease.
Owner:APOGEE THERAPEUTICS INC
Antibodies that bind interleukin 13 and methods of use
PendingEP4540284A4Peptide/protein ingredientsDigestive systemAntiendomysial antibodiesWhite blood cell
Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL- 13 and / or IgE.
Owner:APOGEE THERAPEUTICS INC
A fusion protein comprising il13
The invention is concerned with a fusion protein comprising interleukin 13 and a regulatory cytokine, for example, an interleukin chosen from interleukin 4, interleukin 10, interleukin 27, interleukin 33, transforming growth factor beta 1, transforming growth factor beta 2, and interleukin 13, a nucleic acid molecule encoding such fusion protein, a vector comprising such nucleic acid molecule, and a host cell comprising such nucleic acid molecule or such vector. The invention further pertains to a method for producing such fusion protein. The fusion protein or a gene therapy vector encoding the fusion protein may be used in the prevention or treatment of a condition characterized by pathological pain, chronic pain, neuro-inflammation and / or or neurodegeneration.
Owner:SYNERKINE PHARMA BV
Antibodies that bind interleukin 13 and methods of use.
Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL- 13 and / or IgE.
Owner:APOGEE BIOLOGICS INC
Methods of administering antibodies that bind to interleukin 13
PendingCN121241066AImmunoglobulins against cytokines/lymphokines/interferonsAntibody ingredientsAntiendomysial antibodiesWhite blood cell
Described herein are methods of administering and methods of using antibodies that bind to interleukin 13 (IL-13). In certain aspects, methods of inhibiting the biological activity of IL-13 are described herein. In certain aspects, the antibodies and methods described herein are useful for the treatment of inflammatory disorders or diseases.
Owner:TINGFENG THERAPY CO LTD